Systemic Lupus Erythematosus (SLE)
The constellation of patchy hair loss, erythematous facial plaques (malar rash), fatigue, arthralgias, and weight loss is systemic lupus erythematosus (SLE), a chronic autoimmune disease that predominantly affects young to middle-aged women and requires prompt recognition to prevent irreversible organ damage.
Clinical Presentation and Diagnosis
Cardinal Features
Cutaneous manifestations are present in the majority of SLE patients and include malar rash (37.69% at presentation), photosensitivity (35.10%), and alopecia (39.29% at presentation), making skin findings a critical diagnostic clue 1.
Patchy hair loss in SLE is typically non-scarring and may present as diffuse thinning or discrete patches; approximately 39% of SLE patients experience hair loss at initial presentation 1.
Malar rash appears as erythematous facial plaques distributed in a butterfly pattern across the cheeks and nasal bridge, sparing the nasolabial folds, and is present in approximately 38% of patients at diagnosis 1.
Constitutional symptoms including fatigue (35.22%) and weight loss (13.43%) are common presenting features and reflect the systemic inflammatory nature of the disease 1.
Musculoskeletal involvement manifests as arthralgias in 68.75% and myalgias in 55.65% of patients at presentation, making joint pain one of the most frequent initial complaints 1.
Diagnostic Approach
Antinuclear antibodies (ANA) are positive in more than 95% of SLE patients and serve as the primary screening test; a negative ANA makes SLE highly unlikely 2.
The 2019 EULAR/ACR classification criteria are 96.1% sensitive and 93.4% specific for SLE and include clinical factors (fever, cytopenia, rash, arthritis, proteinuria) plus immunologic measures (SLE-specific autoantibodies and low complement levels) 3.
Targeted serologic testing should include anti-double-stranded DNA antibodies, anti-Smith antibodies, complement levels (C3, C4), complete blood count to assess for cytopenias, and urinalysis to screen for proteinuria indicating lupus nephritis 3.
Hematologic abnormalities occur in approximately 54% of SLE patients and may include anemia, leukopenia, lymphopenia, or thrombocytopenia 4.
Organ System Involvement and Prognosis
Renal Disease
Lupus nephritis develops in approximately 40% of SLE patients and represents one of the most serious complications; 10% of those with lupus nephritis progress to end-stage kidney disease within 10 years 3.
Proteinuria on urinalysis is a critical screening tool and warrants immediate nephrology referral for kidney biopsy to determine the class of lupus nephritis and guide immunosuppressive therapy 3.
Distinguishing SLE from Other Conditions
Adult-onset Still's disease (AOSD) presents with high-spiking quotidian fevers (>39°C), salmon-pink evanescent rash on trunk and proximal limbs (not face), and polyarthritis, but lacks the malar rash and alopecia characteristic of SLE 5.
Subacute cutaneous lupus erythematosus (SCLE) shows less frequent systemic involvement than SLE, with hematologic disorders in only 8% versus 54% in SLE, and photosensitivity is more prominent (86% in SCLE versus 46% in SLE) 4.
Alopecia areata presents with discrete round patches of complete hair loss with exclamation-mark hairs on dermoscopy, lacks facial rash and systemic symptoms, and is not associated with positive ANA or other lupus serologies 6, 7.
Treatment Framework
First-Line Therapy
Hydroxychloroquine is standard of care for all SLE patients and has been associated with significant reduction in mortality, disease activity, and morbidity; it should be initiated immediately upon diagnosis 3.
The primary treatment goal is achieving disease remission or quiescence, defined by minimal symptoms, low autoimmune inflammatory markers, and minimal systemic glucocorticoid requirement while on maintenance immunomodulatory therapy 3.
Additional Immunosuppression
Immunosuppressive agents including azathioprine, mycophenolate mofetil, and cyclophosphamide are used for moderate to severe disease manifestations, particularly when organ-threatening involvement is present 3.
Biologic therapies recently approved by the FDA include belimumab (for active SLE and lupus nephritis), voclosporin (for lupus nephritis), and anifrolumab (for active SLE), offering additional options for refractory disease 3.
Glucocorticoid Management
- Systemic glucocorticoids are often required for disease control but should be minimized to the lowest effective dose to reduce long-term toxicity including osteoporosis, avascular necrosis, and metabolic complications 3.
Critical Pitfalls to Avoid
Do not dismiss hair loss and fatigue as benign conditions in young women; when accompanied by facial rash and arthralgias, these symptoms mandate ANA testing and rheumatology evaluation to rule out SLE 1.
Do not delay nephrology referral when proteinuria is detected, as early aggressive treatment of lupus nephritis significantly reduces progression to end-stage kidney disease 3.
Do not confuse the salmon-pink truncal rash of AOSD with the fixed malar rash of SLE; AOSD rash is evanescent, appears with fever spikes, and spares the face 5.
Do not overlook the psychological impact of chronic disease, disfiguring rash, and hair loss; approximately 90% of SLE patients are female, and the cosmetic and systemic burden profoundly affects quality of life 3.
Do not attribute all symptoms to SLE without considering alternative diagnoses; lichen sclerosus, psoriasis, and other dermatologic conditions may coexist and require distinct management 5.